1-8 of 8
Timothy R. Wilson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations

Smruthy Sivakumar, Dexter X. Jin, Ruchita Rathod, Jeffrey Ross, Lewis C. Cantley, Maurizio Scaltriti, Jessica W. Chen, Katherine E. Hutchinson, Timothy R. Wilson, Ethan S. Sokol, Neil Vasan
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1125–1136.
https://doi.org/10.1158/1078-0432.CCR-22-2270
Published: 14 March 2023
View article titled, Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <em>PIK3CA</em> Mutations
Open the PDF for Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <em>PIK3CA</em> Mutations in another window
Includes: Supplementary data
Journal Articles

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results

Geoffrey J. Lindeman, Tharu M. Fernando, Rebecca Bowen, Katarzyna J. Jerzak, Xinni Song, Thomas Decker, Frances Boyle, Steve McCune, Anne Armstrong, Catherine Shannon, Gianfilippo Bertelli, Ching-Wei Chang, Rupal Desai, Kushagra Gupta, Timothy R. Wilson, Aulde Flechais, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3256–3267.
https://doi.org/10.1158/1078-0432.CCR-21-3811
Published: 02 August 2022
View article titled, VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
Open the PDF for VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results in another window
Includes: Supplementary data
Journal Articles

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2196.
https://doi.org/10.1158/1078-0432.CCR-22-1108
Published: 13 May 2022
View article titled, Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <em>NTRK</em> Fusion–Positive Solid Tumors
Open the PDF for Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with <em>NTRK</em> Fusion–Positive Solid Tumors in another window
Journal Articles

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, Christian Rolfo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1302–1312.
https://doi.org/10.1158/1078-0432.CCR-21-3597
Published: 01 April 2022
View article titled, Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <em>NTRK</em> Fusion-Positive Solid Tumors
Open the PDF for Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With <em>NTRK</em> Fusion-Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

Komal Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid Aljumaily, Philippe L. Bedard, Jasgit C. Sachdev, Lara Dunn, Helen Won, John Bond, Surai Jones, Heidi M. Savage, Maurizio Scaltriti, Timothy R. Wilson, Michael C. Wei, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 447–459.
https://doi.org/10.1158/1078-0432.CCR-20-2657
Published: 19 January 2021
View article titled, Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <em>PIK3CA</em>-Mutant Cancers
Open the PDF for Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <em>PIK3CA</em>-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

Patrick Y. Wen, Timothy F. Cloughesy, Alan G. Olivero, Kari M. Morrissey, Timothy R. Wilson, Xuyang Lu, Lars U. Mueller, Alexandre F. Coimbra, Benjamin M. Ellingson, Elizabeth Gerstner, Eudocia Q. Lee, Jordi Rodon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1820–1828.
https://doi.org/10.1158/1078-0432.CCR-19-2808
Published: 15 April 2020
View article titled, First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma
Open the PDF for First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma in another window
Journal Articles

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Maura N. Dickler, Cristina Saura, Donald A. Richards, Ian E. Krop, Andrés Cervantes, Philippe L. Bedard, Manish R. Patel, Lajos Pusztai, Mafalda Oliveira, Alison K. Cardenas, Na Cui, Timothy R. Wilson, Thomas J. Stout, Michael C. Wei, Jerry Y. Hsu, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (18): 4380–4387.
https://doi.org/10.1158/1078-0432.CCR-18-0613
Published: 14 September 2018
View article titled, Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
Open the PDF for Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Antoni Ribas, Jiang Li, Hartmut Koeppen, Mark Merchant, Richard Neve, Jeff Settleman, Yibing Yan, Elicia Penuel, Luciana Burton, Emily Chan, Jing Peng, Eva Lin, Yulei Wang, Jeff Sosman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): PR6.
https://doi.org/10.1158/1078-0432.MECHRES-PR6
Published: 04 March 2013
View article titled, Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors
Open the PDF for Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors in another window